Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37056065)

  • 1. Exploration of NPC2 as a Potential Biomarker for Immunotherapy Using RNA-seq and Protein Data - A New Hypothesis.
    Lu W; Li D; Tao F; Chen Q; Fan S; Ma Y; Dong H; Hu Y; Yue C
    Endocr Metab Immune Disord Drug Targets; 2023; 23(10):1340-1353. PubMed ID: 37056065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NPC2 as a Prognostic Biomarker for Glioblastoma Based on Integrated Bioinformatics Analysis and Cytological Experiments.
    Wei D; Shen S; Lin K; Lu F; Zheng P; Wu S; Kang D
    Front Genet; 2021; 12():611442. PubMed ID: 33777094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
    Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
    Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.
    Zhao S; Ji W; Shen Y; Fan Y; Huang H; Huang J; Lai G; Yuan K; Cheng C
    BMC Cancer; 2022 Dec; 22(1):1274. PubMed ID: 36474171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and validation of an immune-based prognostic score model in glioblastoma.
    Qin Z; Zhang X; Chen Z; Liu N
    Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.
    You W; Ke J; Chen Y; Cai Z; Huang ZP; Hu P; Wu X
    Front Immunol; 2022; 13():864244. PubMed ID: 35720314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
    Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
    Front Immunol; 2022; 13():844736. PubMed ID: 35592314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data.
    Wang X; Jiang S; Zhou X; Wang X; Li L; Tang J
    Oncol Res; 2023; 31(5):697-714. PubMed ID: 37547756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
    Dai L; Guo X; Xing Z; Tao Y; Liang W; Shi Z; Hu W; Zhou S; Wang X
    BMC Cancer; 2023 Jan; 23(1):102. PubMed ID: 36717836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.
    Wu J; Wang Y; Jiang Z
    J Gastrointest Cancer; 2021 Mar; 52(1):150-159. PubMed ID: 32077004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
    Han J; Puri RK
    J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXC6/8/10/13 predict poor prognosis and associate with immune infiltrations in glioblastoma.
    Yu M; Yu S; Zhou W; Yi B; Liu Y
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108293. PubMed ID: 34763232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Niemann-Pick Type C2 protein expression in multiple cancers using a novel NPC2 monoclonal antibody.
    Liao YJ; Lin MW; Yen CH; Lin YT; Wang CK; Huang SF; Chen KH; Yang CP; Chen TL; Hou MF; Arthur Chen YM
    PLoS One; 2013; 8(10):e77586. PubMed ID: 24147030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of CKS1B as a prognostic indicator and a predictive marker for immunotherapy in pancreatic cancer.
    Li L; Wang J; Zhang Z; Yang Q; Deng Z; Zou W; Ge X; Pan K; Li C; Liu R
    Front Immunol; 2022; 13():1052768. PubMed ID: 36405738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively.
    Tu Z; Ouyang Q; Long X; Wu L; Li J; Zhu X; Huang K
    Front Immunol; 2022; 13():837512. PubMed ID: 35401558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
    Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
    Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.